{"id":1523,"date":"2026-10-01T09:42:54","date_gmt":"2026-10-01T04:12:54","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-01\/"},"modified":"2026-10-05T20:29:22","modified_gmt":"2026-10-05T14:59:22","slug":"torntpharm-share-price-today-2026-10-01","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-01\/","title":{"rendered":"Why Torrent Pharma Shares Fell 2.82% Today: Sector Weakness | 1 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div data-approved-layout=\"1061-v1\" class=\"wt-article-v4\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: TORNTPHARM<\/strong> \u00b7 1 October 2026 \u00b7 Dated market coverage<\/p>\n<div style=\"flex-wrap:wrap;gap:7px;margin:8px 0 14px;\" class=\"wt-price-strip\">\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Price<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b94,756.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Change<\/div>\n<div style=\"font-weight:900;color:#b42318;margin-top:2px;overflow-wrap:anywhere;\">-2.82%<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">High \/ Low<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b94,810.50 \/ \u20b94,725.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Prev. Close<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b94,894.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Volume<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">2.28L<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Updated<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">01:30 PM<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f7fbff;border:1px solid #cfe1f2;border-left:4px solid #2e7db2;border-radius:10px;padding:13px 15px;margin:12px 0 18px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#1f4d70;margin-bottom:6px;\" class=\"wt-card-title\">Key Takeaways<\/div>\n<ul style=\"margin:0;padding-left:18px;\">\n<li>TORRENT PHARMACEUTICALS L was trading<strong>2.82% lower<\/strong>at \u20b94,756.00 and around the middle of the day&#8217;s trading range. <\/li>\n<li><strong>Likely reason:<\/strong>Sector-wide weakness and recent profit-taking. <\/li>\n<li>Cash volume was around<strong>69% of the 20-day average full-session volume<\/strong>, so participation remained below an average full session. <\/li>\n<\/ul><\/div>\n<h2>Why Torrent Pharmaceuticals L Shares Are Falling 2.82% Today<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Torrent Pharmaceuticals shares traded lower in the session, moving down by 2.82% to \u20b94,756.00 compared to its previous close of \u20b94,894.00. The stock opened at \u20b94,774.50 and hovered near the lower end of its intraday range, touching a low of \u20b94,725.00 against a high of \u20b94,810.50. Trading volume remained subdued at approximately 2.28 lakh shares, which is notably lower than its 5-day and 20-day averages.<\/p>\n<p class=\"wt-copy\">The broader market also experienced downward pressure, with the Nifty falling 1.35% and the Nifty Pharma sector benchmark dropping 1.34%. Torrent Pharmaceuticals&#8217; pullback is closely aligned with the broader weak sentiment across pharmaceutical equities, extending a corrective phase that has seen the stock decline roughly 5.02% over the past five sessions and 5.53% over the past month.<\/p>\n<p class=\"wt-copy\">While recent corporate updates include disclosures regarding an acquisition and postal ballot outcomes, no single specific catalyst was announced today to explain the session&#8217;s decline. The price movement appears primarily driven by general sector weakness and profit-taking following recent consolidation, alongside lighter-than-average participation.<\/p>\n<\/div>\n<div style=\"border:1px solid #c9d9e7;border-left:5px solid #1f7b92;border-radius:10px;background:#f5fbfd;padding:14px 16px;margin:15px 0 20px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#174c5d;margin-bottom:6px;\" class=\"wt-card-title\">Likely Reason for Today&#8217;s Move<\/div>\n<div style=\"font-weight:850;color:#20384a;margin-bottom:6px;\">Sector-wide weakness and recent profit-taking<\/div>\n<div style=\"\">The stock&#8217;s decline is largely in line with broader weakness in the Nifty Pharma sector and broader markets, compounded by subdued trading volumes. There is no direct company-specific catalyst reported today to account for the move.<\/div>\n<ul style=\"margin:8px 0 0;padding-left:18px;\">\n<li>Nifty Pharma sector down 1.34%<\/li>\n<li>Volume significantly lower than 5-day and 20-day averages<\/li>\n<li>5-day return down 5.02%<\/li>\n<\/ul><\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div style=\"gap:10px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Acquisition Disclosure Filed Under Regulation 30<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">28-Sep-2026<\/div>\n<div style=\"color:#34495d;\">Torrent Pharmaceuticals submitted a regulatory disclosure pursuant to Regulation 30 of the SEBI Listing Regulations regarding an ongoing acquisition update. The filing keeps markets informed on strategic corporate developments as the company continues to expand its portfolio. Such disclosures are part of standard compliance regarding material corporate actions.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Postal Ballot Scrutinizer&#8217;s Report and Shareholder Approval<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">07-Sep-2026<\/div>\n<div style=\"color:#34495d;\">The company submitted the Scrutinizer&#8217;s report on the postal ballot to the stock exchanges following the conclusion of voting by shareholders. This procedural filing formalizes the approval of resolutions put forth by the management for various corporate items. Voting results reflect shareholder alignment with governance and strategic resolutions.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Appointment of Independent Director<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">30-Jul-2026<\/div>\n<div style=\"color:#34495d;\">Torrent Pharmaceuticals announced the appointment of Shanti Ekambaram as an Independent Director of the company effective July 30, 2026. The board change brings experienced leadership to strengthen oversight and governance structures. The transition was formally communicated to the exchanges in compliance with listing requirements.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div style=\"gap:12px;margin:11px 0 22px;\">\n<div style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:5px solid #cc922c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#8c6318;margin-bottom:9px;\" class=\"wt-card-title\">Promoter Pledge \/ Encumbrance<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Promoter Holding<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">60.78%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">68.31% previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f5f8fb;border:1px solid #d5e0ea;border-left:5px solid #6a849c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#405d76;margin-bottom:9px;\" class=\"wt-card-title\">Recent Ownership \/ Shareholding<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">FII\/FPI<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">17.97%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">15.44% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Mutual Funds<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">8.27%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">4.94% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Institutional<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">30.84%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">25.27% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">MF Schemes<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">44<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">42 previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div style=\"border:1px solid #d5e0ea;border-radius:11px;background:#f7f9fc;padding:14px 15px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"color:#34495d;margin-bottom:10px;\">Mutual funds increased their aggregate stake to<strong>8.27%<\/strong>from <strong>4.94%<\/strong>in the previous quarter. The number of disclosed MF\/UTI shareholders was 44, versus 42 in the previous quarter. <\/div>\n<div style=\"gap:8px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">AXIS MUTUAL FUND TRUSTEE LIMITED A\/C AXIS MUTUAL FUND A\/C<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">4.89M shares \u2022 1.28%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">20-JUL-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">KOTAK CONTRA FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">4.50M shares \u2022 1.18%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">20-JUL-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">HDFC MUTUAL FUND &#8211; HDFC INNOVATION FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">3.91M shares \u2022 1.03%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">20-JUL-2026<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>What to Watch Next<\/h2>\n<ul style=\"\">\n<li>Performance relative to the Nifty Pharma index during recovery phases<\/li>\n<li>Delivery percentage and volume pickup at crucial support zones<\/li>\n<li>Updates regarding ongoing integration and strategic acquisitions<\/li>\n<\/ul>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<h3 style=\"margin:13px 0 4px;\">Why is TORRENT PHARMACEUTICALS L share price falling today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">The stock&#8217;s decline is largely in line with broader weakness in the Nifty Pharma sector and broader markets, compounded by subdued trading volumes. There is no direct company-specific catalyst reported today to account for the move.<\/p>\n<h3 style=\"margin:13px 0 4px;\">How strong is trading participation today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">Participation is moderate rather than exceptional. Volume is about 0.69x the latest 20-day average.<\/p>\n<div style=\"color:#606b78;border-top:1px solid #e1e7ef;padding-top:13px;margin-top:22px;\"><strong>Disclaimer:<\/strong>Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting. <\/div>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-09-29\/\">Why Torrent Pharma Share Price is Down Today | TORNTPHARM Analysis \u2014 29 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/torntpharm\/\">More Torrent Pharmaceuticals L news and dated analysis \u2192<\/a><\/p>\n<p><strong>Article by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-01\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-01\/\"}, \"headline\": \"Why Torrent Pharma Shares Fell 2.82% Today: Sector Weakness | 1 October 2026\", \"description\": \"Torrent Pharmaceuticals shares declined 2.8% amid broader pharma sector weakness. Explore the market context, volume trends, and recent corporate developments.\", \"datePublished\": \"2026-10-01T04:12:54Z\", \"dateModified\": \"2026-10-05T14:43:53.354897+00:00\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/torntpharm-company-news-2026-10-01.jpg\"]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Torrent Pharmaceuticals shares declined 2.8% amid broader pharma sector weakness. Explore the market context, volume trends, and recent corporate developments.<\/p>\n","protected":false},"author":1,"featured_media":2882,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Why Torrent Pharma Shares Fell 2.82% Today: Sector Weakness | 1 October 2026","_witty_meta_description":"Torrent Pharmaceuticals shares declined 2.8% amid broader pharma sector weakness. Explore the market context, volume trends, and recent corporate developments.","_witty_primary_phrase":"Torrent Pharmaceuticals L share price 2026-10-01","_witty_reason_label":"Sector-wide weakness and recent profit-taking","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[149],"class_list":["post-1523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-torntpharm"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/1523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=1523"}],"version-history":[{"count":6,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/1523\/revisions"}],"predecessor-version":[{"id":2885,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/1523\/revisions\/2885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/2882"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=1523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=1523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=1523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}